Summary
220.03 1.11(0.51%)05/08/2024
Biogen Inc (BIIB)
Biogen Inc (BIIB)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -1.15 | 1.89 | 6.80 | -9.00 | -10.88 | -30.38 | -4.43 | 6,904.16 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 218.88 | |
| Open | 221.52 | |
| High | 221.98 | |
| Low | 216.08 | |
| Volume | 914,377 | |
| Change | -2.55 | |
| Change % | -1.15 | |
| Avg Volume (20 Days) | 1,364,648 | |
| Volume/Avg Volume (20 Days) Ratio | 0.67 | |
| 52 Week Range | 189.44 - 319.76 | |
| Price vs 52 Week High | -31.55% | |
| Price vs 52 Week Low | 15.54% | |
| Range | -1.19 | |
| Gap Up/Down | -0.88 | |
Fundamentals | ||
| Market Capitalization (Mln) | 31,991 | |
| EBIDTA | 2,519,800,064 | |
| PE Ratio | 27.3993 | |
| PEG Ratio | 6.2424 | |
| WallStreet Target Price | 285.12 | |
| Book Value | 104.4850 | |
| Earnings Per Share | 7.9900 | |
| EPS Estimate Current Quarter | 3.4500 | |
| EPS Estimate Next Quarter | 3.9400 | |
| EPS Estimate Current Year | 15.6100 | |
| EPS Estimate Next Year | 17.4100 | |
| Diluted EPS (TTM) | 7.9900 | |
| Revenues | ||
| Profit Marging | 0.1207 | |
| Operating Marging (TTM) | 0.2728 | |
| Return on asset (TTM) | 0.0486 | |
| Return on equity (TTM) | 0.0805 | |
| Revenue TTM | 9,663,099,904 | |
| Revenue per share TTM | 66.6880 | |
| Quarterly Revenue Growth (YOY) | -0.0700 | |
| Quarterly Earnings Growth (YOY) | 0.0110 | |
| Gross Profit (TTM) | 7,895,100,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 27.3993 | |
| Forward PE | 13.0039 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 1.9465 | |
| Revenue Enterprise Value | 3.5683 | |
| EBITDA Enterprise Value | 17.2165 | |
| Shares | ||
| Shares Outstanding | 145,596,992 | |
| Shares Float | 145,050,907 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.03 | |
| Insider (%) | 0.16 | |
| Institutions (%) | 93.25 | |
04/29 10:03 EST - InvestorPlace
7 Retirement Stocks to Buy at a 52-Week Low in April
One of the best ways to keep your portfolio safe while generating consistent income is in safe, dividend-paying retirement stocks at 52-week lows. It's even better if you're buying into a reputable company that's paid out dividends for years, and is on sale.
7 Retirement Stocks to Buy at a 52-Week Low in April
One of the best ways to keep your portfolio safe while generating consistent income is in safe, dividend-paying retirement stocks at 52-week lows. It's even better if you're buying into a reputable company that's paid out dividends for years, and is on sale.
04/24 18:18 EST - The Motley Fool
Why Biogen Stock Leaped Nearly 5% Higher Today
The biotech handily beat the average analyst estimate for profitability. Investors were surely happy about this, but they might have been more impressed by the sales of a promising drug that recently won approval.
Why Biogen Stock Leaped Nearly 5% Higher Today
The biotech handily beat the average analyst estimate for profitability. Investors were surely happy about this, but they might have been more impressed by the sales of a promising drug that recently won approval.
04/24 17:05 EST - CNBC Television
3-Stock Lunch: TXN, BIIB & CMG
Jerry Castellini, Castle Ark co-founder, joins ‘Power Lunch' to discuss plays for three stocks including: Texas Instruments, Biogen and Chipotle Mexican.
3-Stock Lunch: TXN, BIIB & CMG
Jerry Castellini, Castle Ark co-founder, joins ‘Power Lunch' to discuss plays for three stocks including: Texas Instruments, Biogen and Chipotle Mexican.
04/24 14:01 EST - Zacks Investment Research
Biogen (BIIB) Q1 Earnings Beat, Stock Up on Alzheimer Drug Uptake
Biogen's (BIIB) first-quarter earnings beat estimates but sales miss the mark. While sales of key drugs like Tecfidera, Tysabri & Spinraza declined, the company's cost-saving efforts show promise.
Biogen (BIIB) Q1 Earnings Beat, Stock Up on Alzheimer Drug Uptake
Biogen's (BIIB) first-quarter earnings beat estimates but sales miss the mark. While sales of key drugs like Tecfidera, Tysabri & Spinraza declined, the company's cost-saving efforts show promise.
04/24 10:36 EST - Zacks Investment Research
Biogen (BIIB) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Biogen (BIIB) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Biogen (BIIB) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Biogen (BIIB) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
04/24 08:51 EST - Barrons
Biogen Stock Rises After Earnings and on Jump in Alzheimer's Drug Sales
Biogen says first-quarter global in-market sales of Leqembi were about $19 million, nearly triple the fourth quarter of 2023.
Biogen Stock Rises After Earnings and on Jump in Alzheimer's Drug Sales
Biogen says first-quarter global in-market sales of Leqembi were about $19 million, nearly triple the fourth quarter of 2023.
04/24 07:45 EST - Invezz
Biogen Q1 2024 results surpass expectation despite revenue decline
Biogen Inc. (NASDAQ: BIIB), a leading biotechnology company, has released its Q1 2024 financial results, showcasing resilience and strategic growth despite facing revenue challenges. In the first quarter of 2024, Biogen reported a revenue of $2.29 billion, which slightly missed expectations by $30 million.
Biogen Q1 2024 results surpass expectation despite revenue decline
Biogen Inc. (NASDAQ: BIIB), a leading biotechnology company, has released its Q1 2024 financial results, showcasing resilience and strategic growth despite facing revenue challenges. In the first quarter of 2024, Biogen reported a revenue of $2.29 billion, which slightly missed expectations by $30 million.
04/24 06:47 EST - CNBC
Biogen tops quarterly profit estimates as cost cuts take hold, Leqembi launch picks up
Alzheimer's drug Leqembi brought in in approximately $19 million in sales for the quarter, up from the $10 million the drug generated last year.
Biogen tops quarterly profit estimates as cost cuts take hold, Leqembi launch picks up
Alzheimer's drug Leqembi brought in in approximately $19 million in sales for the quarter, up from the $10 million the drug generated last year.
04/19 10:40 EST - Zacks Investment Research
What's in Store for Biogen (BIIB) This Earnings Season?
Biogen's (BIIB) sales in the first quarter are likely to have been hurt by lower sales of its multiple sclerosis drugs, while sales of Spinraza are likely to have been moderate.
What's in Store for Biogen (BIIB) This Earnings Season?
Biogen's (BIIB) sales in the first quarter are likely to have been hurt by lower sales of its multiple sclerosis drugs, while sales of Spinraza are likely to have been moderate.
04/19 10:20 EST - Zacks Investment Research
Gear Up for Biogen (BIIB) Q1 Earnings: Wall Street Estimates for Key Metrics
Besides Wall Street's top -and-bottom-line estimates for Biogen (BIIB), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.
Gear Up for Biogen (BIIB) Q1 Earnings: Wall Street Estimates for Key Metrics
Besides Wall Street's top -and-bottom-line estimates for Biogen (BIIB), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.
04/01 18:56 EST - Zacks Investment Research
Biogen Inc. (BIIB) Falls More Steeply Than Broader Market: What Investors Need to Know
In the closing of the recent trading day, Biogen Inc. (BIIB) stood at $214.83, denoting a -0.37% change from the preceding trading day.
Biogen Inc. (BIIB) Falls More Steeply Than Broader Market: What Investors Need to Know
In the closing of the recent trading day, Biogen Inc. (BIIB) stood at $214.83, denoting a -0.37% change from the preceding trading day.
03/26 12:26 EST - Zacks Investment Research
CHMP to Delay Nod on Biogen (BIIB), Eisai's Alzheimer's Drug
Per Biogen (BIIB)/Eisai, the delay in CHMP recommendation for lecanemab is entirely related to procedural reasons at the EMA and is not related to the companies' regulatory filing.
CHMP to Delay Nod on Biogen (BIIB), Eisai's Alzheimer's Drug
Per Biogen (BIIB)/Eisai, the delay in CHMP recommendation for lecanemab is entirely related to procedural reasons at the EMA and is not related to the companies' regulatory filing.
03/22 07:29 EST - Reuters
EU drug regulator does not refer to Eisai-Biogen Alzheimer's drug in meeting notes
The European Union's medicines regulator did not mention Eisai and Biogen's Alzheimer's drug in its notes and recommendations on Friday.
EU drug regulator does not refer to Eisai-Biogen Alzheimer's drug in meeting notes
The European Union's medicines regulator did not mention Eisai and Biogen's Alzheimer's drug in its notes and recommendations on Friday.
03/19 14:16 EST - Seeking Alpha
Biogen Inc. (BIIB) Stifel 2024 Virtual CNS Days (Transcript)
Biogen Inc. (BIIB) Stifel 2024 Virtual CNS Days (Transcript)
Biogen Inc. (BIIB) Stifel 2024 Virtual CNS Days (Transcript)
Biogen Inc. (BIIB) Stifel 2024 Virtual CNS Days (Transcript)
03/18 18:56 EST - Zacks Investment Research
Here's Why Biogen Inc. (BIIB) Gained But Lagged the Market Today
Biogen Inc. (BIIB) reachead $219.40 at the closing of the latest trading day, reflecting a +0.04% change compared to its last close.
Here's Why Biogen Inc. (BIIB) Gained But Lagged the Market Today
Biogen Inc. (BIIB) reachead $219.40 at the closing of the latest trading day, reflecting a +0.04% change compared to its last close.
03/15 09:11 EST - 24/7 Wall Street
$10 Biotech Stock Wall Street Says Will Be Up Over 200% This Year
Take This Retirement Quiz To Get Matched With An Advisor Now (Sponsored) Are you ready for retirement?
$10 Biotech Stock Wall Street Says Will Be Up Over 200% This Year
Take This Retirement Quiz To Get Matched With An Advisor Now (Sponsored) Are you ready for retirement?
03/14 12:36 EST - Zacks Investment Research
Why Is Biogen Inc. (BIIB) Up 2.6% Since Last Earnings Report?
Biogen Inc. (BIIB) reported earnings 30 days ago. What's next for the stock?
Why Is Biogen Inc. (BIIB) Up 2.6% Since Last Earnings Report?
Biogen Inc. (BIIB) reported earnings 30 days ago. What's next for the stock?
03/12 18:56 EST - Zacks Investment Research
Biogen Inc. (BIIB) Stock Falls Amid Market Uptick: What Investors Need to Know
Biogen Inc. (BIIB) concluded the recent trading session at $227.36, signifying a -1.18% move from its prior day's close.
Biogen Inc. (BIIB) Stock Falls Amid Market Uptick: What Investors Need to Know
Biogen Inc. (BIIB) concluded the recent trading session at $227.36, signifying a -1.18% move from its prior day's close.
03/08 15:21 EST - CNBC Television
Three-Stock Lunch: Biogen, DocuSign & Gap
Gina Sanchez, Lido Advisors chief market strategist, joins 'Power Lunch' to discuss stock plays for three stocks, including Biogen, DocuSign and Gap.
Three-Stock Lunch: Biogen, DocuSign & Gap
Gina Sanchez, Lido Advisors chief market strategist, joins 'Power Lunch' to discuss stock plays for three stocks, including Biogen, DocuSign and Gap.
03/05 18:56 EST - Zacks Investment Research
Here's Why Biogen Inc. (BIIB) Fell More Than Broader Market
Biogen Inc. (BIIB) closed at $217.23 in the latest trading session, marking a -1.71% move from the prior day.
Here's Why Biogen Inc. (BIIB) Fell More Than Broader Market
Biogen Inc. (BIIB) closed at $217.23 in the latest trading session, marking a -1.71% move from the prior day.